This pilot, prospective, observational drug study aims to evaluate the efficacy, tolerability and safety of topical and oral antifungals in the treatment of onychomycosis caused by yeasts, dermatophytic moulds and non-dermatophytic moulds as well as correlate the scores in the MALDI-TOF method for the 'identification of genus and species of higher fungi utilizing the comparison between identification in direct optical microscopy, culture examination and optical microscopy and macroscopic and onychoscopic clinical aspects. Furthermore, an optional substudy will evaluate the drug resistance of clinical isolates using molecular or genetic methods.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change of Onychomycosis Severity Index (OSI)
Timeframe: week 0,12,24,36,52
Safety and Tolerability: Established from patient incidence of Treatment-Emergent Adverse Events
Timeframe: Monitored from screening visit to end of study visit (52 week)
Complete Cure at 12 months in the Target Toes
Timeframe: Week 52